# TRADE DXd

Source: https://onco.cc/trials/nct06533826/  
OnCo record `nct06533826` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TRADE DXd studies the order of two antibody-linked drugs, trastuzumab deruxtecan and datopotamab deruxtecan. It asks how well one works after the other stops controlling the cancer.

## Summary

TRADE DXd studies the order of two antibody-linked drugs, trastuzumab deruxtecan and datopotamab deruxtecan. It asks how well one works after the other stops controlling the cancer.

Interventional study registered as NCT06533826, sponsored by Ana C Garrido-Castro, MD. Registry phase: 2. Registry enrollment is 357 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT06533826
- Phase: 2
- Setting: HER2-negative metastatic breast cancer, including HER2-low disease
- Sponsor: Ana C Garrido-Castro, MD

## Sources

- ClinicalTrials.gov NCT06533826: https://clinicaltrials.gov/study/NCT06533826
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT06533826

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct06533826.json